ETF Building Blocks Content Hub Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Content Hub Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
ETF Building Blocks Content Hub Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
ETF Building Blocks Content Hub Drug Pricing Reform Unlikely to Affect Smaller Biotech Companies By Tom LydonJune 24, 2021
ETF Building Blocks Content Hub Turn Healthcare Breakthroughs into ETF Gains with This Fund By Tom LydonJune 21, 2021
ETF Building Blocks Content Hub Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Content Hub As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Innovative ETFs Content Hub Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
ETF Building Blocks Content Hub Capture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO’ By Tom LydonFebruary 10, 2021
ETF Building Blocks Content Hub ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
ETF Building Blocks Content Hub Don’t Miss Out on Rampant Biotech Mergers with the SBIO ETF By Tom LydonJanuary 13, 2021
Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
ETF Building Blocks Content Hub How Increased FDA Activity Can Benefit ETFs in Your Portfolio By Tom LydonNovember 19, 2020
ETF Building Blocks Content Hub A Healthcare ETF Review: Biotech Beckons under Biden By Tom LydonNovember 9, 2020
ETF Building Blocks Content Hub More than Just COVID: Hot ETFs for Medical Breakthroughs By Tom LydonNovember 5, 2020
ETF Building Blocks Content Hub For 2021 Upside, Bet on the SBIO Biotech ETF By Tom LydonOctober 29, 2020
ETF Building Blocks Content Hub Post-Election Considerations for a Nifty Biotech ETF By Tom LydonOctober 7, 2020
